CN Patent

CN119101031A — 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途

Assigned to Beijing Huayi Health Drug Research Center · Expires 2024-12-10 · 1y expired

What this patent protects

本申请涉及用于治疗或预防冠状病毒感染的3CL蛋白酶抑制剂及其用途。具体地，本申请涉及式(I)化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前体药、或其代谢物，及其在制备用于治疗或预防冠状病毒感染或由冠状病毒引起的疾病或症状的药物中的用途。

USPTO Abstract

本申请涉及用于治疗或预防冠状病毒感染的3CL蛋白酶抑制剂及其用途。具体地，本申请涉及式(I)化合物或其同位素标记化合物、或其光学异构体、几何异构体、互变异构体或异构体混合物、或其药学上可接受的盐、或其前体药、或其代谢物，及其在制备用于治疗或预防冠状病毒感染或由冠状病毒引起的疾病或症状的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN119101031A
Jurisdiction
CN
Classification
—
Expires
2024-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Huayi Health Drug Research Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.